JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)Sham Mailankody, Andrzej Jakubowiak, Todd DeVries et al.|Blood|2018Cited by 124
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).Sham Mailankody, Sandy W. Wong, Andrzej Jakubowiak et al.|Journal of Clinical Oncology|2020Cited by 122
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium studyAndrzej Jakubowiak, Kenneth C. Anderson|British Journal of Haematology|2012Cited by 62
Potent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical modelsAndrew Stefka, Andrzej Jakubowiak|Cancer Medicine|2019Cited by 19